Cassel Salpeter Welcomes New Managing Directors Margery Fischbein And Deborah F. Aghib, Ph. D., Expanding Its Healthcare Group
February 10, 2020
Driven by strong sustained growth and an unwavering commitment to providing top-tier independent investment banking services for middle-market and emerging growth companies, Cassel Salpeter & Co. announced the strategic additions of Margery Fischbein and Deborah F. Aghib, Ph.D. Two exceptional professionals with over 65 combined years of executive experience, Ms. Fishbein and Dr. Aghib will join Ira Leiderman and the team as managing directors of the healthcare group, one of a broad spectrum of industries the firm assists, and an increasingly in-demand vertical for the company.
In these roles, Ms. Fishbein and Dr. Aghib will advise owners and boards of directors of middle-market, private and public companies on a variety of M&A transactions, equity and debt financings, strategic licensing and partnering, and financial advisory assignments across a range of healthcare verticals.
“As part of our firm’s accelerated forward momentum, we warmly welcome these seasoned industry experts, who join our longtime healthcare managing director, Ira Leiderman,” said chairman and co-founder James Cassel. “Their experience, track record, and client-first approach is perfectly in line with our commitment to providing world-class services. Together with Ira, they will spearhead dynamic new initiatives and help satisfy significant demand for our healthcare services.”
MARGERY FISCHBEIN
Prior to joining Cassel Salpeter, Ms. Fishbein was head of Healthcare Investment Banking for Seaport Global and FBR & Co., and head of East Coast Biotechnology Investment Banking for JMP Securities. Ms. Fischbein also held senior executive positions at the biotechnology companies ImClone Systems and Human Genome Sciences. She began her career rising to senior vice president at Lehman Brothers and then as managing director of investment banking at JPMorgan Chase and Citigroup.
Ms. Fishbein earned a master’s in business administration from Harvard Business School and a bachelor’s degree from Harvard University.
DEBORAH F. AGHIB, PH.D.
Prior to joining Cassel Salpeter, Dr. Aghib was a private equity consultant for CRG LP, a global healthcare-focused investment firm and industry pioneer. Before that, she was the chief business development executive for Stellar Biotechnologies, Inc., and also held other senior executive positions. Dr. Aghib was also an Independent Director on the Stellar Biotechnologies, Inc. board of directors. She is currently a board member of the OpenWorm Foundation.
Dr. Aghib holds a Ph.D. in Molecular and Cellular Biology from the University of Milan (Italy) and a Ph.D. in Human Genetics from the University of Pavia (Italy), and a M.Sc degree in Biological Sciences from the University of Milan (Italy).
About Cassel Salpeter & Co.
Cassel Salpeter & Co. LLC is an independent investment banking firm that provides advice to middle market and emerging growth companies in the U.S. and worldwide. Together, the firm’s professionals have extensive experience providing private and public companies with a broad spectrum of investment banking and financial advisory services, including: mergers and acquisitions; equity and debt capital raises; fairness and solvency opinions; valuations; and restructurings, such as 363 sales and plans of reorganization. Co-founded by James Cassel and Scott Salpeter, the firm provides objective, unbiased, results-focused services that clients need to achieve their goals. Personally involved at every stage of all engagements, the firm’s senior professionals have forged relationships and completed hundreds of transactions and assignments nationwide. The firm’s headquarters are in Miami. Member FINRA and SIPC.
